title: Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy.
abstract: The current study shows the therapeutic outcome achieved in triple negative breast cancer (TNBC) by simultaneously antagonizing miR-21-induced antiapoptosis and miR-10b-induced metastasis, using antisense-miR-21-PS and antisense-miR-10b-PS delivered by polymer nanoparticles (NPs). We synthesized the antisense-miR-21 and antisense-miR-10b loaded PLGA-b-PEG polymer NPs and evaluated their cellular uptake, serum stability, release profile, and the subsequent synchronous blocking of endogenous miR-21 and miR-10b function in TNBC cells in culture, and tumor xenografts in living animals using molecular imaging. Results show that multitarget antagonization of endogenous miRNAs could be an efficient strategy for targeting metastasis and antiapoptosis in the treatment of metastatic cancer. Targeted delivery of antisense-miR-21 and antisense-miR-10b coloaded urokinase plasminogen activator receptor (uPAR) targeted polymer NPs treated mice showed substantial reduction in tumor growth at very low dose of 0.15 mg/kg, compared to the control NPs treated mice and 40% reduction in tumor growth compared to scramble peptide conjugated NPs treated mice, thus demonstrating a potential new therapeutic option for TNBC.
authors: Molecular Imaging Program at Stanford, Bio-X Program, Department of Radiology, Stanford University School of Medicine, Stanford University, 3155 Porter Drive, Palo Alto, California 94304, United States.
authors: Rammohan
authors: R
authors: Devulapally
authors: Molecular Imaging Program at Stanford, Bio-X Program, Department of Radiology, Stanford University School of Medicine, Stanford University, 3155 Porter Drive, Palo Alto, California 94304, United States.
authors: Narayana M
authors: NM
authors: Sekar
authors: Molecular Imaging Program at Stanford, Bio-X Program, Department of Radiology, Stanford University School of Medicine, Stanford University, 3155 Porter Drive, Palo Alto, California 94304, United States.
authors: Thillai V
authors: TV
authors: Sekar
authors: Molecular Imaging Program at Stanford, Bio-X Program, Department of Radiology, Stanford University School of Medicine, Stanford University, 3155 Porter Drive, Palo Alto, California 94304, United States.
authors: Kira
authors: K
authors: Foygel
authors: Molecular Imaging Program at Stanford, Bio-X Program, Department of Radiology, Stanford University School of Medicine, Stanford University, 3155 Porter Drive, Palo Alto, California 94304, United States.
authors: Tarik F
authors: TF
authors: Massoud
authors: Molecular Imaging Program at Stanford, Bio-X Program, Department of Radiology, Stanford University School of Medicine, Stanford University, 3155 Porter Drive, Palo Alto, California 94304, United States.
authors: Jürgen K
authors: JK
authors: Willmann
authors: Molecular Imaging Program at Stanford, Bio-X Program, Department of Radiology, Stanford University School of Medicine, Stanford University, 3155 Porter Drive, Palo Alto, California 94304, United States.
authors: Ramasamy
authors: R
authors: Paulmurugan
mesh_terms: D000818:Animals; D001692:Biological Transport; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000235:genetics; D002471:Cell Transformation, Neoplastic; D004337:Drug Carriers / Q000737:chemistry; D005260:Female; D015316:Genetic Therapy; D006801:Humans; D051379:Mice; D035683:MicroRNAs / Q000737:chemistry* / Q000235:genetics* / Q000378:metabolism; D050997:Nanomedicine / Q000379:methods*; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D011092:Polyethylene Glycols / Q000737:chemistry*; D011098:Polyglactin 910 / Q000737:chemistry*; D020871:RNA Stability; D055293:Receptors, Urokinase Plasminogen Activator / Q000235:genetics; D064726:Triple Negative Breast Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*
chemical_list: D004337:Drug Carriers; C547183:MIRN10 microRNA, human; C524940:MIRN21 microRNA, human; D035683:MicroRNAs; D055293:Receptors, Urokinase Plasminogen Activator; C102418:poly(lactic-glycolic acid)-poly(ethyleneglycol) copolymer; D011098:Polyglactin 910; D011092:Polyethylene Glycols
keywords: PLGA; anti-miRs; antisense-miRNAs; bioluminescence; cancer therapy; in vivo molecular imaging; microRNA; nanoparticles; targeted delivery
references: J Pharmacol Sci. 2010;114(3):276-80
references: 20953119
references: Cancer Gene Ther. 2010 Jun;17(6):398-408
references: 20094072
references: Cell Res. 2008 Mar;18(3):350-9
references: 18270520
references: Appl Biochem Biotechnol. 2011 Dec;165(7-8):1628-51
references: 21947761
references: Theranostics. 2013;3(12):964-85
references: 24396507
references: Bioessays. 2010 Oct;32(10):894-904
references: 21105295
references: Curr Cancer Drug Targets. 2009 Feb;9(1):32-71
references: 19200050
references: Blood. 2007 Aug 15;110(4):1330-3
references: 17496199
references: FEBS Lett. 2008 Dec 24;582(30):4113-6
references: 19032954
references: Breast Cancer Res. 2010;12(5):210
references: 21067538
references: Nat Med. 2011 Feb;17(2):211-5
references: 21240262
references: Nat Rev Drug Discov. 2003 Mar;2(3):214-21
references: 12612647
references: Methods Mol Biol. 2009;544:589-98
references: 19488725
references: Nature. 2007 Oct 11;449(7163):682-8
references: 17898713
references: Nat Biotechnol. 2010 Apr;28(4):341-7
references: 20351690
references: J Colloid Interface Sci. 2009 Oct 1;338(1):184-92
references: 19595359
references: Lab Invest. 2008 Dec;88(12):1358-66
references: 18794849
references: Nat Mater. 2009 Jun;8(6):526-33
references: 19404239
references: Breast Cancer Res Treat. 2012 Feb;131(3):1049-59
references: 22057972
references: J Biomater Sci Polym Ed. 2010;21(3):303-14
references: 20178687
references: Breast Cancer Res. 2011;13(1):R2
references: 21219636
references: J Control Release. 2008 Feb 11;125(3):193-209
references: 18083265
references: Mol Ther Nucleic Acids. 2013 Apr 16;2:e84
references: 23591808
references: Nat Rev Cancer. 2011 Jan;11(1):59-67
references: 21160526
references: Nanoscale. 2013 Dec 21;5(24):12120-5
references: 24154605
references: Clin Cancer Res. 2013 May 1;19(9):2355-67
references: 23493348
references: Mol Pharm. 2012 May 7;9(5):1481-8
references: 22482958
references: Nat Rev Cancer. 2006 Apr;6(4):259-69
references: 16557279
references: Br J Pharmacol. 2009 May;157(2):179-94
references: 19366348
references: Nature. 2005 Dec 1;438(7068):685-9
references: 16258535
references: Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014 Jan-Feb;6(1):40-60
references: 23996830
references: Cell. 2009 Jun 12;137(6):1005-17
references: 19524505
references: Cancer Res. 2008 Oct 1;68(19):8164-72
references: 18829576
references: Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):E1695-704
references: 22685206
references: Nucleic Acids Res. 2005;33(4):1290-7
references: 15741182
references: Cancer Res. 2005 Jul 15;65(14):6029-33
references: 16024602
references: Oncogene. 2008 Apr 3;27(15):2128-36
references: 17968323
references: Nat Biotechnol. 2010 Apr;28(4):331-2
references: 20379176
references: Am J Clin Pathol. 2007 Nov;128(5):830-6
references: 17951207
references: Breast Cancer (Auckl). 2012;6:9-19
references: 22259248
references: Expert Rev Mol Diagn. 2009 May;9(4):325-41
references: 19435455
references: Nucleic Acids Res. 2011 Mar;39(6):e38
references: 21212128
references: Acc Chem Res. 2011 Oct 18;44(10):1009-17
references: 21761902
references: Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
references: 18663219
references: Nat Mater. 2011 May;10(5):389-97
references: 21499315